Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Quantin

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Pageof 9